nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—Urinary hesitation—Fludarabine—lymphatic system cancer	0.0857	0.0857	CcSEcCtD
Trihexyphenidyl—Blindness—Fludarabine—lymphatic system cancer	0.0635	0.0635	CcSEcCtD
Trihexyphenidyl—Ileus paralytic—Vincristine—lymphatic system cancer	0.0497	0.0497	CcSEcCtD
Trihexyphenidyl—Sinus bradycardia—Mitoxantrone—lymphatic system cancer	0.0427	0.0427	CcSEcCtD
Trihexyphenidyl—Cognitive impairment—Methotrexate—lymphatic system cancer	0.0399	0.0399	CcSEcCtD
Trihexyphenidyl—Blindness—Vincristine—lymphatic system cancer	0.0388	0.0388	CcSEcCtD
Trihexyphenidyl—Paranoia—Carmustine—lymphatic system cancer	0.033	0.033	CcSEcCtD
Trihexyphenidyl—Cognitive disorder—Methotrexate—lymphatic system cancer	0.0241	0.0241	CcSEcCtD
Trihexyphenidyl—Agitation—Teniposide—lymphatic system cancer	0.0161	0.0161	CcSEcCtD
Trihexyphenidyl—Weight decreased—Bleomycin—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Trihexyphenidyl—Confusional state—Teniposide—lymphatic system cancer	0.0144	0.0144	CcSEcCtD
Trihexyphenidyl—Agitation—Fludarabine—lymphatic system cancer	0.0141	0.0141	CcSEcCtD
Trihexyphenidyl—Tachycardia—Teniposide—lymphatic system cancer	0.0139	0.0139	CcSEcCtD
Trihexyphenidyl—Confusional state—Fludarabine—lymphatic system cancer	0.0126	0.0126	CcSEcCtD
Trihexyphenidyl—Vomiting—Mechlorethamine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Trihexyphenidyl—Rash—Mechlorethamine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Trihexyphenidyl—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Trihexyphenidyl—Weight decreased—Vincristine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Trihexyphenidyl—Weight decreased—Mitoxantrone—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Teniposide—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Trihexyphenidyl—Drowsiness—Mitoxantrone—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Trihexyphenidyl—Nausea—Mechlorethamine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Trihexyphenidyl—Hallucination—Carmustine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Trihexyphenidyl—Hallucination—Vincristine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Trihexyphenidyl—Constipation—Fludarabine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Trihexyphenidyl—Asthenia—Teniposide—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Trihexyphenidyl—Confusional state—Bleomycin—lymphatic system cancer	0.00927	0.00927	CcSEcCtD
Trihexyphenidyl—Vision blurred—Carmustine—lymphatic system cancer	0.00927	0.00927	CcSEcCtD
Trihexyphenidyl—Vomiting—Teniposide—lymphatic system cancer	0.00908	0.00908	CcSEcCtD
Trihexyphenidyl—Agitation—Carmustine—lymphatic system cancer	0.00904	0.00904	CcSEcCtD
Trihexyphenidyl—Asthenia—Fludarabine—lymphatic system cancer	0.009	0.009	CcSEcCtD
Trihexyphenidyl—Rash—Teniposide—lymphatic system cancer	0.009	0.009	CcSEcCtD
Trihexyphenidyl—Dermatitis—Teniposide—lymphatic system cancer	0.00899	0.00899	CcSEcCtD
Trihexyphenidyl—Headache—Teniposide—lymphatic system cancer	0.00894	0.00894	CcSEcCtD
Trihexyphenidyl—Agitation—Vincristine—lymphatic system cancer	0.00863	0.00863	CcSEcCtD
Trihexyphenidyl—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00862	0.00862	CcSEcCtD
Trihexyphenidyl—Nausea—Teniposide—lymphatic system cancer	0.00848	0.00848	CcSEcCtD
Trihexyphenidyl—Confusional state—Carmustine—lymphatic system cancer	0.0081	0.0081	CcSEcCtD
Trihexyphenidyl—Vomiting—Fludarabine—lymphatic system cancer	0.00798	0.00798	CcSEcCtD
Trihexyphenidyl—Rash—Fludarabine—lymphatic system cancer	0.00791	0.00791	CcSEcCtD
Trihexyphenidyl—Dermatitis—Fludarabine—lymphatic system cancer	0.0079	0.0079	CcSEcCtD
Trihexyphenidyl—Headache—Fludarabine—lymphatic system cancer	0.00786	0.00786	CcSEcCtD
Trihexyphenidyl—Tachycardia—Carmustine—lymphatic system cancer	0.00784	0.00784	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00758	0.00758	CcSEcCtD
Trihexyphenidyl—Confusional state—Mitoxantrone—lymphatic system cancer	0.00753	0.00753	CcSEcCtD
Trihexyphenidyl—Nausea—Fludarabine—lymphatic system cancer	0.00745	0.00745	CcSEcCtD
Trihexyphenidyl—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00728	0.00728	CcSEcCtD
Trihexyphenidyl—Somnolence—Carmustine—lymphatic system cancer	0.00714	0.00714	CcSEcCtD
Trihexyphenidyl—Constipation—Carmustine—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Trihexyphenidyl—Somnolence—Mitoxantrone—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Carmustine—lymphatic system cancer	0.00662	0.00662	CcSEcCtD
Trihexyphenidyl—Asthenia—Bleomycin—lymphatic system cancer	0.0066	0.0066	CcSEcCtD
Trihexyphenidyl—Constipation—Vincristine—lymphatic system cancer	0.00655	0.00655	CcSEcCtD
Trihexyphenidyl—Constipation—Mitoxantrone—lymphatic system cancer	0.00638	0.00638	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00615	0.00615	CcSEcCtD
Trihexyphenidyl—Vomiting—Bleomycin—lymphatic system cancer	0.00585	0.00585	CcSEcCtD
Trihexyphenidyl—Drowsiness—Methotrexate—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Trihexyphenidyl—Rash—Bleomycin—lymphatic system cancer	0.0058	0.0058	CcSEcCtD
Trihexyphenidyl—Dermatitis—Bleomycin—lymphatic system cancer	0.00579	0.00579	CcSEcCtD
Trihexyphenidyl—Asthenia—Carmustine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Trihexyphenidyl—Asthenia—Vincristine—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Trihexyphenidyl—Nausea—Bleomycin—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Trihexyphenidyl—Asthenia—Mitoxantrone—lymphatic system cancer	0.00536	0.00536	CcSEcCtD
Trihexyphenidyl—Dizziness—Carmustine—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Trihexyphenidyl—Vomiting—Carmustine—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Trihexyphenidyl—Dizziness—Vincristine—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Trihexyphenidyl—Rash—Carmustine—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Trihexyphenidyl—Dermatitis—Carmustine—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Trihexyphenidyl—Headache—Carmustine—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Trihexyphenidyl—Vomiting—Vincristine—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Trihexyphenidyl—Rash—Vincristine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Trihexyphenidyl—Dermatitis—Vincristine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Trihexyphenidyl—Headache—Vincristine—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Trihexyphenidyl—Nausea—Carmustine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Trihexyphenidyl—Vomiting—Mitoxantrone—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Trihexyphenidyl—Rash—Mitoxantrone—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Trihexyphenidyl—Dermatitis—Mitoxantrone—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Trihexyphenidyl—Headache—Mitoxantrone—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Trihexyphenidyl—Nausea—Vincristine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Trihexyphenidyl—Nausea—Mitoxantrone—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Trihexyphenidyl—Vision blurred—Methotrexate—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Trihexyphenidyl—Confusional state—Methotrexate—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Trihexyphenidyl—Somnolence—Methotrexate—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Trihexyphenidyl—Asthenia—Methotrexate—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Trihexyphenidyl—Dizziness—Methotrexate—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Trihexyphenidyl—Vomiting—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Trihexyphenidyl—Rash—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Trihexyphenidyl—Dermatitis—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Trihexyphenidyl—Headache—Methotrexate—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Trihexyphenidyl—Nausea—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
